Lima, M.T., Lima, J.G., de Andrade, M.F., & Bergmann, A. (2014). Low-level laser therapy in secondary lymphedema after breast cancer: Systematic review. Lasers in Medical Science, 29, 1289–1295.
STUDY PURPOSE: To discuss the treatment of breast cancer-related lymphedema with low-level laser therapy (LLLT), its usefulness, and safety
TYPE OF STUDY: General review/\"semi\" systematic review
PHASE OF CARE: Late effects and survivorship
Three of four studies were able to show statistical significance in limb volume after treatment; however, follow-up times varied. Carati et al. reported a significance of 0.017 (89.7 ml versus 32.1 ml) three-months post-treatment, Kaviani et al. reported a greater reduction in all weeks except one (no statistical reference), Kozanoglu et al. reported a greater reduction with LLLT (p = 0.04 at post-treatment and p = 0.02 at 12 months), and Lau et al. reported a statistically significant reduction at four weeks post-treatment (448.2 to 320.9 ml, p = 0). Two studies reported significance in a decrease in tissue hardness. No improvement in subjective symptoms were reported (pain, range of motion [ROM], heaviness, grip strength); however, Lau et al. reported significantly decreased mean scores on the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire in the treatment group (p = 0.04) post-treatment, but they were not statistically significant at four weeks follow-up.
Nurses need to be knowledgeable of clinical trials involving LLLT and stay current with lymphedema management, as well as educate patients on LLLT.
Lilleby, K., Garcia, P., Gooley, T., McDonnnell, P., Taber, R., Holmberg, L., … Bensinger, W. (2006). A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation, 37, 1031–1035.
This was a randomized trial.
Cryotherapy was associated with improved outcomes. Research is needed to determine the required length of cryotherapy.
Liljegren, A., Gunnarsson, P., Landgren, B. M., Robeus, N., Johansson, H., & Rotstein, S. (2012). Reducing vasomotor symptoms with acupuncture in breast cancer patients treated with adjuvant tamoxifen: a randomized controlled trial. Breast Cancer Research and Treatment, 135, 791-798.
The study evaluated the value of true acupuncture in management of hot flashes in women with breast cancer receiving tamoxifen.
Patients on tamoxifen who experienced vasomotor symptoms were randomly assigned to true acupuncture or control acupuncture groups. All patients were treated for 20 minutes twice weekly for 5 weeks in an outpatient clinic. In the true acupuncture group, 8 needles were inserted at defined points. In the control group, needles did not penetrate the skin, but were rotated until the patient felt a superficial sensation on the skin. In the control group, the needles were placed at 8 sites, as well. Study data were collected at baseline, week 6, and week 18.
The study enrolled 74 women with a mean age of 58 years.
The study was conducted in an outpatient clinic in Sweden.
PHASE OF CARE: Transition phase after active treatment
The study was a single-blind, randomized, sham-controlled trial.
Instruments/measures included:
There were no significant differences between groups in frequency of hot flushes and sweating over time. The acupuncture group reported less severity of symptoms of sweating at night ( p = .03). Both groups demonstrated significant improvement in symptoms over time. Of those who received true acupuncture, 69.4% thought they had receiving true acupuncture, while 63.9% of those in the control group thought they had received true acupuncture, suggesting that patient blinding was accomplished. One adverse event of bleeding and bruising was reported in 1 control patient.
Findings suggest little difference in symptoms between those who received acupuncture versus those who received sham acupuncture. Acupuncture may have some benefit, but it is unclear if this also reflects a placebo effect from the intervention.
Study limitations included:
This study provides limited evidence regarding the effect of acupuncture for vasomotor symptoms in women with breast cancer treated with tamoxifen. It does demonstrate questions regarding potential placebo effects of acupuncture or placebo effects of sham acupuncture procedures that complicate research design in this area. Appropriate placebo or comparison control groups for this type of research need to be identified.
Likun, Z., Xiang, J., Yi, B., Xin, D., & Tao, Z.L. (2011). A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults. Oncologist, 16, 207–216.
To evaluate the effectiveness and adverse effects of palonosetron in prevention of chemotherapy-induced nausea and vomiting (CINV)
Databases searched were Medline, Embase, Chinese VIP database, Evidence-Based Medicine Review, Cochran Central Register, Current Controlled Trials, National Research Register, and Clinicaltrials.gov.
Search keywords were palonosetron, chemotherapy-induced nausea and/or vomiting, CINV.
Studies were included if they were randomized, controlled trials (RCTs) that compared palonosetron with first generation 5-HT3 receptor antagonists (RAs).
Studies were excluded if they involved pediatric patients.
An initial 235 references were identified. Eight RCTs were identified for inclusion. Studies were evaluated in terms of randomization, blinding, allocation concealment, crossover design, and intention to treat analysis.
The final sample included eight RCTs involving 3,592 patients receiving highly or moderately emetogenic chemotherapy.
In comparing the effectiveness of palonosetron with first-generation 5-HT3 RAs for acute CINV
In comparing the effectiveness of palonosetron with first-generation 5-HT3 RAs for delayed CINV, both the 0.25-mg and 0.75-mg palonosetron doses yielded better prevention of delayed CINV (p < 0.00001).
Studies that included dexamethasone (two trials) reported that dexamethasone plus palonosetron reduced the risk of CINV by 38%–40% (p < 0.00001).
The 0.75-mg palonosetron dose was associated with a higher risk of constipation than lower-dose palonosetron or first-generation medications (p = 0.01).
Meta-analysis demonstrated that palonosetron was more effective in risk reduction for both acute and delayed CINV than first-generation 5-HT3 RAs. This effect was seen with both 0.25- and 0.75-mg dosages, and with or without concomitant use of dexamethasone. A 0.75-mg dose of palonosetron was associated with more constipation.
A limited number of studies were used in some subgroup analysis, and no studies looked at lower-dose palonosetron and dexamethasone compared to first-generation drugs. This research is warranted, because lower dosages are associated with less constipation.
Palonosetron is a safe and effective alternative for prevention of CINV. Nurses need to be aware of the potential for constipation with higher dosages, particularly in patients with other treatments that affect bowel function.
Lihua, P., Su, M., Zejun, Z., Ke, W., & Bennett, M.I. (2013). Spinal cord stimulation for cancer-related pain in adults. Cochrane Database of Systematic Reviews, 2, CD009389.
To review the evidence regarding spinal cord stimulation for pain management in cancer
This study is a systematic review.
Databases searched were the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Chinese Biomedical Database (up to July 2012), National Cancer Institute trial registry, World Health Organization International Clinical Trials Registry Platform, and clinicaltrials.gov, supported by the National Institutes of Health. The authors also hand-searched relevant articles.
Search terms were text words combined with medical subject headings (MeSH) terms for electrostimulation and cancer.
Studies were included in the review if they were randomized controlled trials (RCTs) or nonrandomized trials comparing spinal cord stimulation with another intervention for cancer pain.
All studies had to report on adult patients.
A total of 430 references were retrieved.
The authors assessed risk of bias from sequence assignment and allocation concealment. No specific rating scale is mentioned. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist was used for observational studies, as no RCTs were found.
The study has clinical applicability for palliative care.
There were very few studies, and prospective studies were pre-post case series reports. More than 80% of patients reported at least a 50% reduction in pain severity, and more than 50% reported reduction in opioid use. Minor complications included headache, asthenia, dizziness, and muscle twitches. Major complications included infection, cerebrospinal fluid leak, pain at electrode sites, and system failure. Follow-up ranged from one week to one year. All studies were of low quality.
There is insufficient evidence to evaluate the potential role of spinal cord stimulation for cancer-related pain control.
Limitations included few publications and low-quality research.
Effectiveness of spinal cord stimulation for management of cancer-related pain cannot be determined. There is a need for high-quality research in this area.
Liguori, V., Guillemin, C., Pesce, G.F., Mirimanoff, R.O., & Bernier, J. (1997). Double-blind, randomized clinical study comparing hyaluronic acid cream to placebo in patients treated with radiotherapy. Radiotherapy and Oncology, 42, 155–161.
To determine if prophylactic use of hyaluronic acid cream postpones acute radiodermatitis or reduces its severity and to evaluate the efficacy of hyaluronic acid to delay the onset of necrosis or to accelerate recovery in case of ulceration
Hyaluronic or placebo cream was applied to irradiated skin area twice daily. The first application was one-to-two hours after the radiation therapy session and the second was in the evening. The topic treatment was continued over a six-week period.
The study took place at Ospedale San Giovanni and Centre Hospitlier Universitaire, both in Switzerland.
The study used a randomized placebo-controlled double-blind trial design.
The prophylactic use of hyaluronic acid cream is shown to reduce the incidence of high-grade radiodermatitis.
Liguori, S., Gottardi, M., Micheletto, G., & Bruno, L. (2010). Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: An open multicentric study. European Review for Medical and Pharmacological Sciences, 14(3), 185–190.
To determine the incidence of visceral pain and to evaluate the efficacy of oxycodone in the context of visceral pain
Patients with visceral pain stopped existing drug treatment and instead used controlled-release oxycodone for 15 days. Conversion was according to international guidelines. Dosage of the study drug was individualized. If by day 7 a patient did not achieve a pain-score reduction of at least 50% or if he or she experienced a severe adverse event, clinicians administered an alternative opioid. Investigators gathered pain scores at baseline and after 3, 7, and 15 days of treatment. The regimen permitted use of rescue medication, morphine sulfate.
Prospective observational single-group trial
All patients who entered the study completed the study. None had to switch to another opioid. Mean dose after titration was 50.1 mg/day controlled-release (CR) oxycodone. At all time points, pain scores had decreased from a baseline mean of 7.04. At day 15, the mean pain score was 2.37 (p < 0.00001). Authors noted some improvement in all domains of the SF-12, but these changes were not statistically significant. Few patients experienced more than mild adverse evens. The most frequent adverse events were nausea, constipation, and sleepiness.
In this study, use of CR oxycodone was associated with significant reduction in mean pain scores over a 15-day period, with minimal adverse events.
This study showed CR oxycodone to be effective in producing significant pain reduction within three days and over 15 days. This finding warrants a study of long-term effect. CR oxycodone is one medication in the armamentarium of opioid formulations for pain management. The side effects of CR oxycodone are those to be expected with opioid use.
Lievens, Y., Haustermans, K., Van den Weyngaert, D., Van den Bogaert, W., Scalliet, P., Hutsebaut, L., . . . Lambin, P. (1998). Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiotherapy and Oncology, 47, 149–153.
To determine the efficacy of oral sucralfate in reducing radiation (RT)-induced acute complications in the treatment of patients with head and neck cancer. This study looked at mucositis and dermatitis.
Patients were given oral sucralfate at a dose of 1 gm six times a day from the onset of RT and continued during the entire treatment.
Two sites in Belgium
The study was a randomized, placebo-controlled, double-blind trial.
Dermatitis scoring scale:
Other variables analyzed were weight, tumor site, and stage; subjective tolerance; dysphagia; nausea and vomiting; dermatitis; mucositis; total dose; and daily fractionation schedule.
Of the initial 102 patients randomized, only 83 were evaluable due to issues of patient nonadherence to the protocol. Compliance was worse in the sucralfate group. There were no differences in mean scores for dermatitis or other symptoms measured between the two study groups.
No clinical evidence indicated that sucralfate reduces acute RT-induced side effects.
Liepe, K., & Kotzerke, J. (2007). A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nuclear Medicine Communications, 28, 623–630.
Prospective, nonrandomized study
These treatments produced mild and reversible side effects, and it is therefore a good option. It is usually used in palliation, but due to low side effects, there is possibility that it might be considered earlier in disease process. Future research could review concomitant treatment with chemotherapy.
Lienard, A., Merckaert, I., Libert, Y., Delvaux, N., Marchal, S., Boniver, J., . . . Razavi, D. (2008). Factors that influence cancer patients’ and relatives’ anxiety following a three-person medical consultation: Impact of a communication skills training program for physicians. Psycho-Oncology, 17, 488–496.
To assess the impact of communication skills training programs on changes in patients’ and relatives’ anxiety following a three-person consultation
Prior to a three-person consultation (physician/patient/caregiver), physicians who had earlier completed a basic training program were randomly assigned to complete a consolidation workshop or to a wait-list for the workshop. To gain study data, patients and relatives completed an anxiety questionnaire and a physiologic distress questionnaire (depression and anxiety) the week before and repeated the anxiety questionnaire one week after the three-person consultation. Physicians chose patients with cancer and their accompanying relatives for an audiotaped consultation. Transcription of the consultations occurred to allow a measurement of quality of consultations. Trained psychologists assessed physician skills in assessment, information, and supportive skills according to a French national rating system used in three previous studies.
A pre/post-test design was used.
No statistically significant differences were found between patients’ and relatives’ sociodemographic characteristics and disease and over time with basic training consultation and the basic training added to the consolidation workshops. A multivariate analysis of variance assessment showed significant change between time in changes in patients’ anxiety following the three-person consultation (p = 0.027). Although anxiety decreased for both patients and relatives following the consultation, none of these changes was significant. There were no significant correlations between changes in patients’ and relatives’ anxiety and physician assessment, information, and supportive skills. In further analyses (mixed-effects modeling), physician communication skills had no influence on changes in patients and relatives following a three-person consultation. Only contextual variables (e.g., type of bad news, type of information transmitted by physicians and self-reported before the consultation) had an effect on changes in anxiety and distress.
The physician training program described did not diminish patient or relative anxiety about cancer following the consultation.
The concept of nurse/patient/caregiver conversations as part of routine nursing care seems appropriate in the U.S. healthcare system that seeks to increase primary care. Although relatives’ and patients’ needs may vary, nurses have strong assessment, information-gathering, and supportive skills to promote health and coping of patients, caregiver relatives, and families either in group formats or individual forums.